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ABSTRACT 
 
This report presents an approach to predict pancreatic cancer using Support Vector Machine Classification 
algorithm. The research objective of this project it to predict pancreatic cancer on just genomic, just clinical and 
combination of genomic and clinical data. We have used real genomic data having 22,763 samples and 154 
features per sample. We have also created Synthetic Clinical data having 400 samples and 7 features per sample 
in order to predict accuracy of just clinical data. To validate the hypothesis, we have combined synthetic clinical 
data with subset of features from real genomic data. In our results, we observed that prediction accuracy, 
precision, recall with just genomic data is 80.77%, 20%, 4%. Prediction accuracy, precision, recall with just 
synthetic clinical data is 93.33%, 95%, 30%. While prediction accuracy, precision, recall for combination of 
real genomic and synthetic clinical data is 90.83%, 10%, 5%. The combination of real genomic and synthetic 
clinical data decreased the accuracy since the genomic data is weakly correlated. Thus we conclude that the 
combination of genomic and clinical data does not improve pancreatic cancer prediction accuracy. A dataset 
with more significant genomic features might help to predict pancreatic cancer more accurately. 
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1. INTRODUCTION 
          Pancreatic Cancer is an ailment in which harmful cells shape in the tissues of the pancreas. Cells in the  
            body begin to grow uncontrollably. Pancreas is located behind the stomach and produce hormones   
            that control sugar. Most of pancreatic cancers commence in the cells that produce these hormones  
            [Journal of Clinical Oncology and Research, 2014]. 
Different cancers have different symptoms. But having a symptom, or even several symptoms, does not 
mean that one will get the disease. Few of the Clinical symptoms for Pancreatic Cancer are Jaundice, 
Floating Bowels, Unintentional Weight Loss, Smoking, Family History of Cancer while genomic symptoms 
are gene mutation in following genes: KRAS, TP53, CDKN2A, SMAD4, genetic gain in chromosome 8q, 
genetic loss in chromosome 9p, presence of genes MLL315, ATM15, KDM6A12 because of structural 
variations and gene mutation. 
 
Prostate cancer is a common and frequent cause of cancer death. In the United States, prostate cancer is the 
most commonly diagnosed visceral cancer; in 2016, there are expected to be approximately 181,000 new 
prostate cancer diagnoses and approximately 26,100 prostate cancer deaths [e.Siegel RL, Cancer statistics, 
2016. - PubMed - NCBI"]. Prostate cancer is second only to skin cancer and lung cancer as the leading 
cause of cancer and cancer death, respectively, in United States men. Worldwide, in 2012 there were 
estimated to be 1,112,000 new cases of prostate cancer and 308,000 prostate cancer deaths, making it the 
second most commonly diagnosed cancer in men and the fifth leading cause of male cancer death [e.Torre 
LA, Global cancer statistics, 2012]. 
The mortality rate of pancreatic cancer patients is approaching 100%. Only 4% of the patients survive 5 
years or more after being diagnosed. All these grim statistics of pancreatic cancer necessitates the urgent 
development of methods to facilitate their early detection and prevention [AB, et al, 2004]. Despite the 
advancement of knowledge in recent years regarding the pathophysiology of pancreatic cancer [D, et al, 
2004] [M, et al, 2004], there is no effective method to diagnose this cancer type early enough to impact the 
treatment outcomes. 
 
 
Prostate Cancer is a very complex disease, and the decision-making process is challenging because it 
requires a fine balance among expected clinical benefit, life expectancy and potential treatment-related 
adverse events [A, et al, 2009]. The prediction of clinical outcomes is therefore critical. Accurate estimates 
of stage and of the likelihood of cancer diagnosis, clinical significance, treatment success, and complications 
are important for patient counseling and informed decision-making. By understanding the most probable 
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endpoint of a patient’s clinical course, physicians may modify treatment and post-treatment strategies in 
order balance benefits and adverse events of treatment. Prediction also allows patients to choose responsibly 
among the different treatment strategies proposed by the clinicians. Properly informing the patient of these 
likelihoods could improve the patient’s satisfaction after treatment [Shariat, 2009]. Thus early prediction of 
Prostate Cancer will help reduce its mortality. 
 
 
 
2. LITERATURE REVIEW 
    2.1 Towards Prediction of Pancreatic Cancer Using SVM Study Model: 
 
Goal of this paper is to Predict Pancreatic Cancer using Support Vector Machine. Some studies [CK, et al, 
1982] [Riboli E, et al, 1983] indicate that tumor variation is a strong symptom of pancreatic cancer. This 
suggests that histological tumor differentiation and lymph node metastasis could be a good predictor for 
pancreatic cancer. Thus this work aims at evaluating following biological properties and provide predictive 
information of cancer cell behavior pre-operatively: “Lymph node metastasis” and “Tumor metastasis” in 
Pancreatic Cancer. This work makes use of accumulated leftover laboratory data which involves many 
features. The clinical tests are considered as an n-dimensional pathological feature set, where n refers to the 
number of clinical tests. By taking the n samples and grouping them by a particular status, this data is used 
to train a classifier, which can then be assessed by the cross-validation technique. 
 
Dataset 
In this study, 174 surgically resected and histologically confirmed common type pancreatic cancer cases at 
the National Cancer Center Hospital in Japan are utilized for the analysis. Tumor differentiation status and 
lymph node metastatic status (N0; negative nodal metastasis or N+; positive nodal metastasis), are used as 
the basis of classification. 
Following two data sets are prepared based on the above classification criteria: Set Diff (tumor 
differentiation between poorly differentiated vs. others) and the Set N1 (N+ vs. N0). For Set Diff, poorly to 
moderately differentiated tumor samples are considered as positive samples, well differentiated tumor 
samples are taken as negative samples. For Set N1, N0 are defined as negative findings while the rest as 
positive, with a total of 86 positive samples. Following clinical laboratory data from the same cancer cases is 
also used: CEA, CA19-9, Glucose, Elastase I, Serum Amylase, C-reactive protein (CRP), Serum Glucose 
(GLU), Fibrin degradation product (FDP), Fibrinogen (FIBG) and Antithrombin III (ATIII). We also use 
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data regarding age, sex, tumor location, tumor size (TS mm), number of lymphocytes (LymphNum) and 
lymphocyte ratio (LymphCell). 
 
Methodology 
To identify important features, feature ranking is done using several available feature selection criteria like 
“entropy”, “t-test”, “ROC”, “bhattacharyya” After feature ranking, “FIBG”, “CA19-9”, “CEA” and 
“Elastase I” are selected as top four features. All the features used for analysis are initially converted into 
several groups: “low”, “normal” and “high” based on the definition of the normal ranges provided by 
National Cancer Center Hospital described in detail in [12]. In order to quantize the features, numbers -1, 0 
and 1 are used to indicate low group, normal range and high group respectively. As a result, 59 data 
instances are used to train the SVM. Integrating the four significant features, a data set of size 59-by-4 (59 
patients and 4 features) is created. 
 
Results and Discussion 
Classification performance of the model used in this paper is compared with other Machine Learning 
techniques like Decision Trees (DT) and K Nearest Neighborhood (KNN). The accuracy of SVM is 70% 
which is better than DT (65%) and KNN (69%). Average Specificity of SVM is 70% which is slightly less 
than DT (79%) and KNN (99%). Average Sensitivity is 70% which shows that this model is very good in 
predictions. AUC values are compared to find out how effective the models are. The proposed model was 
employed to predict new pancreatic cancer samples and the accuracy of this experiment was 72% which is 
quite remarkable. Thus the approaches used for feature selection and outlier detection help in classifying 
correctly. 
 
 
     2.2 Machine learning of clinical performance in a pancreatic cancer database: 
 
Approach 
The majority of predictive models in modern oncology literature are generated by regression algorithms, 
particularly linear regression, logistic regression, and Cox’s proportional hazard model [Y, et al, 2003] [R, et 
al, 2002] [JF, 2004]. Author has used both the traditional algorithms (linear and logistic regression), and 
machine learning classification algorithms (Bayesian nets, decision trees, k -nearest-neighbor, neural 
networks, among others) to generate prediction models. A clinical database consisting of 91 patient 
treatments over the course of several years was constructed. The accuracies of machine learning prediction 
models were statistically compared to those generated by traditional methods over this clinical database. Set 
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of prediction target attributes for which to develop prediction models were selected which include tumor 
size, T-staging, N-staging, vasculature involvement, tumor histology, malignancy, survival rates, and ECOG 
scores at 6-month, 9-month, and 12-month follow-up intervals. For each of these target attributes, 
performance of the prediction algorithms was tested on a data set extracted from the clinical database by 
removing the value of the selected target attribute from each patient treatment instance. Predicted values of 
the target attribute based on the remaining attributes were compared with the value of the target attribute in 
the full database. 
 
Dataset 
Pancreatic cancer patients seen over a three-year period at the Dept. of Surgical Oncology at the University 
of Massachusetts Memorial Hospital in Worcester, MA were considered. Complete screening, treatment, 
and follow-up records were retrospectively compiled from the hospital’s Meditech electronic record system 
into this clinical database. Supervision by the medical staff was provided for the interpretation of ambiguous 
or incomplete records. A total of 91 evaluations for pancreatic cancer treatment were done between April 
2003 and May 2006, representing 87 unique patients. Among the patients, 49 (56%) were female. Among 
the tumors evaluated, 75 (82%) were deemed potentially resectable, 7 (8%) locally advanced/unresectable, 
and 9 (10%) metastatic or equivocal. A total of 74 (81%) resections were subsequently performed with a 
surgical success rate (complete excision of tumor) of 96%. Radiotherapy was assigned in 37 (41%) 
evaluations, chemotherapy in 39 (43%) evaluations, and palliative measures in 11 (12%) evaluations. One of 
the challenges with the data set was a relatively small number (91) of patient instances were available for 
this study. Studies are often constrained by the number of patients seen at an institution, or the rarity of 
certain disease etiologies [M, et al, 1997]. The number of patients available in this study has proved 
sufficient in other pancreatic cancer studies [R, et al, 2002] [J, et al, 2004] 
 
Methodology 
Weka Machine Learning workbench [I, et al, 2005] is used for all classification and regression algorithm 
implementation. The algorithms used are ZeroR (numeric mode or majority class prediction), linear 
regression (minimizes sum of squared errors between linear combination of attribute values and prediction 
target) [H, 1974] [JL, 1995] and logistic regression [S, et al, 1992]. Data preprocessing methods used are 
Minimum Description Length (MDL) discretization and correlation-based feature selection. MDL 
discretization transforms numeric attributes into nominal attributes by binning the attribute values relative to 
changes in the target classification, as measured by the minimum description length (MDL) principle [UM, 
et al, 1993]. Correlation-based feature selection (CFS) heuristically selects a subset of attributes such that 
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attributes in the subset exhibit high correlation to the target class and low correlation to each other [MA 
2000]. Clinical prediction models are then generated using classification for nominal targets and regression 
for numeric targets. Metrics of predictive performance are evaluated over 10 iterations of 10-fold cross-
validation with random re-seeding. Performance of classification models is evaluated via the mean 
classification accuracy (percentage correct) across these 100 repetitions. Regression models are evaluated by 
calculating r-squared values which define percentage of response variance accounted for by the prediction 
model. 
 
Result and Analysis 
Classification performance of the data mining techniques apparently is equivalent or better than that of 
conventional logistic regression. This distinction has a tendency to be most noteworthy over the original 
data with no preprocessing. When preprocessing is connected as CFS feature selection and MDL attribute 
discretization, logistic regression execution enhances extraordinarily. Performance of the data mining 
methods also improves with preprocessing. However, in several experiments the accuracy difference 
between typical data mining performance values and logistic regression performance is no longer large 
enough to be statistically significant at the level p<0.05. The author has compared the performance of 1240 
generated data mining predictive models against logistic regression. The overall classification performance 
of the data mining methods is generally comparable or statistically superior to logistic regression. 
 
Conclusion and Future Work 
The present paper has described the application of machine learning models to data mining over a database 
of cancer patient clinical performance with a view toward predicting specific outcomes, including patient 
survival and quality of life. The data mining methods considered here delivered comparable or superior 
predictive performance to that of traditional multivariate regression methods for nearly all prediction targets. 
Future work should consider further advantages of data mining, particularly the expressiveness of the 
resulting models and their potential usefulness to clinicians in understanding the factors that influence 
disease state and in making clinical decisions. One technical gap to consider in future work is the trade-off 
between smaller feature-rich data set, and other available data sets which provide larger numbers of patients 
but comparatively less individual detail. 
 
     2.3 Prediction of pancreatic cancer survival through automated selection of predictive models: 
 
Motivation 
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The quality of the predictions produced by a given machine learning method varies across patients. In 
particular, the method that provides the best predictive model for one patient will not necessarily be 
optimal for another patient. The latter fact suggests that overall predictive performance across all 
patients could be improved if it were possible to reliably predict, for each patient, what machine learning 
method will provide the best performance for that particular patient. The selected method can then be 
used to make predictions for the patient in question. This is the approach described in this paper. 
 
Dataset 
A clinical database containing retrospective records of 60 patients treated by resection for pancreatic 
adenocarcinoma at the University Of Massachusetts Memorial Hospital in Worcester was created. Each 
patient record is described by 190 fields comprising information about preliminary outlook, personal and 
family medical history, diagnostic tests, tumor pathology, treatment course, surgical proceedings, and 
length of survival. The attributes are divided into three major categories: 111 pre-operative attributes, 78 
peri-operative attributes, and the target attribute. The prediction target (or target attribute) of this 
analysis is survival time, measured as the number of months between diagnosis and death. All patients 
considered in this study have known dates of death, hence the potential statistical issue of data censoring 
that is, prematurely “cut oﬀ ” data, does not occur. 
 
Experimental Protocol 
Select Level 0 Classifiers: Each of the machine learning strategies is connected under thought with and 
without highlight determination to the dataset and recorded the subsequent precision detailed by the 10 
reiterations of 10-overlap cross approval technique is recorded. For each of the machine learning 
systems, the majority of the element choice methodologies are tried with a changing number of ascribes 
to be chosen. As a rule, highlight determination expanded the precision of the machine learning 
strategies. At that point the main 3 most precise models among all models are chosen: the ones with and 
the ones without highlight choice. Select the Level 1 Classifier: Once the main 3 performing level 0 
models are distinguished, creator tentatively figured out what subset of those 3 beat models together 
with what level 1 machine realizing method would yield the model-selector meta-classifier with the 
most noteworthy prescient precision. As over, all machine learning strategies with and without highlight 
choice (and permitting the extent of the chose credit set to shift) are considered for level 1 show 
development. Take note of that for this situation, include determination is connected to the level 1 
dataset, not to the first dataset. The model selector meta-classifier with the most noteworthy prescient 
exactness is then revealed. 
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Results and Analysis 
The naıve Bayes (NB) classifier clearly benefits from attribute selection in this study: its classification 
accuracy is higher when trained over a relatively small number of selected attributes. On the other hand, 
the Bayes Network (BN) classifier performs best when allowed to operate over a larger set of attributes 
that has undergone little or no selection. The different results in the two cases are explained by the fact 
that the naıve Bayes technique, unlike Bayes Networks, is based on the assumption of conditional 
independence among the non-class attributes given the class. Attribute selection extracts a smaller set of 
less-correlated predictive attributes, thus bringing the attribute set closer to satisfying the conditional 
independence assumption. 
 
 
Table 1: Classification accuracy for nine-month survival dataset 
 
This paper has presented a new approach to combining predictive methods through automated meta-
learning, and an evaluation of this technique for the prediction of pancreatic cancer survival using a 
database of retrospective patient records. The experimental evaluation presented in this paper focuses on 
predicting survival time of pancreatic cancer patients based on attributes such as demographic 
information, initial symptoms, and diagnostic test results. Individual predictors considered include 
various machine learning techniques as well as logistic regression. The evaluation results show that the 
proposed technique of model selection meta-learning produces predictions that are better than those of 
the individual predictive methods. Also, the proposed technique outperforms the standard meta-learning 
techniques of bagging, boosting, and stacking in the experiments conducted for this paper. 
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     2.4 Data Mining Techniques for Prognosis in Pancreatic Cancer: 
 
Approach 
Goal of this paper [Floyd, et al., 2007] is to predict expected survival time of the patient. Instead of 
comparing the accuracies of models constructed using Machine Learning algorithms, this paper says that 
since the collaborators know the patients in the dataset, asking them to predict a patient's survival given a set 
of attributes from this dataset would likely not be representative of their ability to predict the expected 
survival of a new patient. Therefore, Logistic Regression and ZeroR are used as benchmark algorithms.Gain 
Ratio, Principal Components, ReliefF, and Support Vector Machines are used for feature selection. These 
algorithms rank the most important features so are run several times, varying the condition on the number of 
features to return. This method is used to determine the optimal feature for a given machine learning 
algorithm. Baseline algorithms are compared with several other machine learning algorithms, including 
artificial neural networks, Bayesian networks, decision trees, naïve Bayes networks, and support vector 
machines. For each dataset, the best combination of feature selection and machine learning algorithm is 
identified. These combinations are compared with ZeroR and logistic regression. An attempt is made to 
improve the classification accuracy by experimenting with both bagging, boosting, stacking, and model 
selector described in the paper. The primary focus in this study is on improving the classification accuracy 
by combining multiple machine learning models generated by the best pairs of feature selection and machine 
learning algorithm. 
The classification accuracy for all experiments is calculated by running ten repetitions, each repetition 
with a different initial random seed, of tenfold cross validation. The models with the highest 
classification accuracy are then selected for further comparison. The classification accuracy of these 
models is compared to the classification accuracy of a model built using logistic regression. Once the 
best combinations of feature selection and machine learning algorithm is found, Bagging is evaluated 
on each of these combinations as a method to reduce the standard deviation of the classification 
accuracy, as decreasing the standard derivation may increase the statistical significance. Boosting is 
evaluated to increase the classification accuracy of each combination. 
 
 
Results 
The highest classification accuracy obtained by constructing models with no feature selection is 
47.5%. There is an overall increase in the classification accuracies as the number of attributes is 
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increased from 10 to 30. When 30 attributes are selected there are several models with 
classification accuracies above 47.5% including ones constructed using artificial neural networks 
with one hidden unit, artificial neural networks with two hidden units, Bayesian networks with one 
parent, and logistic regression. After this peak at 30 attributes most models show a gradual decrease 
in classification accuracy as the number of attributes selected increases. The classification accuracy 
of this model continues to increase until it peaks when 60 attributes are selected. The best model 
with no feature selection resulted from a model constructed using a Bayesian network with a 
maximum of two parents. 
 
 
     2.5 Premalignant Pancreatic Cancer Diagnosis Using Proteomic Pattern Analysis: 
 
Approach 
The goal of this paper [Htike, et al., 2015] is to predict, given a mass spectrum derived from a serum 
sample, whether or not the sample comes from a patient with early pancreatic cancer. Two steps are 
performed in pre-processing: base-line correction and smoothing. Base-line correction is done because a 
major of the m/z ratios have non-zero intensity values or spurious peaks because of systematic error, 
background noise, and chemical noise. Therefore, the true mass spectrum without the contaminants is 
estimated. A ‘top-hat’ filter to perform baseline correction is proposed. It entails subtracting the 
observed spectrum its morphological opening. Spectrum smoothing is then performed next in order to 
alleviate very high frequency components [Coombes, et al, 2005]. A wavelet noise removal technique is 
also proposed. It entails dividing the mass spectrum into components of different scales and estimating 
the wavelet coefficients [Alpaydin, 2010]. Coefficients corresponding to high frequency components are 
then discarded in order to smoothen the spectrum. 
 
 
Feature Extraction and Classification 
RELIEF is used as a Feature Selection algorithm. It is used select 300 best m/z ratios that best 
discriminate pancreatic cancer. A proteomic mass spectrum is now represented by a 300-dimensional 
feature vector [Kononenko, et al, 1997]. A hybrid technique called a logistic model tree [Landwehr, et 
al, 2005] to classify 300-dimensional feature vector is used. The proposed logistic model tree applies 
LogitBoost with simple regression functions as base learners in order to fit the logistic models. 
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Experiments 
Dataset from University of Pennsylvania is used [Hingorani, et al, 2003]. Dataset contains 181 serum 
samples where 80 samples are pancreatic intraepithelial neoplasia samples and the remaining 101 
samples are healthy or control samples. The mass spectrum of each serum sample contains 6771 m/z 
ratios that range from 800 to 11992.91. Leave-one-out cross-validation is used where one sample was 
held out as the validation data while the remaining samples served as training data. The whole process 
was repeated multiple times such that each sample got held out exactly once as the validation data. The 
results were then averaged to produce an estimator to the accuracy of the proposed pancreatic cancer 
diagnosis system. Throughout all the experiments, minimum number of boosting iterations of 50, the 
maximum number of boosting iterations of 1500, and the heuristic threshold value of 60 as parameters 
of the logistic model tree were used. Table 2 lists the summary of the leave-one-out cross-validation 
results. 
 
 
 
 
 
 
 
 
Table 2: LOOCV Results Summary 
 
134 out of 181 samples are predicted accurately giving an accuracy of 75 %. Cohen coefficient value is 
0.47. Root Mean Square Error is found to be 0.4470 which is quite less. Table 4 displays the results. The 
true positive rate of the disease class is lower than that of the control class. Moreover, the false positive 
rate for the tumor class is likewise lower than that of the control class. This implies the framework 
creates more negative forecasts than positive expectations. As per the author, this maybe because of the 
imbalanced class distribution. 
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                 Table 3: Detailed Results by Output Class 
 
Conclusion 
Given the mass spectrum of a serum sample, the system predicts whether the serum shows signs of 
premalignant pancreatic cancer. This system has achieved an accuracy of 74.0331% in early 
premalignant pancreatic cancer detection for this dataset. The accuracy is not that high because this is a 
very challenging problem owing to the fact that in the early stages of cancer, there are only miniscule 
differences in the proteomes. However, the preliminary experimental results are quite promising. As 
future work, the author mentions that he will perform optimization of the system parameters to further 
boost the performance of the system. He would also like to test this framework on a wide range of other 
types of cancer. 
 
 
    2.6 Combining PubMed knowledge and EHR data to develop a weighted Bayesian network for    
          pancreatic cancer prediction 
 
Approach 
In this paper [Zhao, et al., 2011], PubMed knowledge and Electronic Health Records is combined 
to develop a weighted Bayesian Network Inference model for pancreatic cancer prediction. 20 
variables that are used to design the BNI models are: age, alcohol or cigarette abuse, abdominal 
pain, fatigue or asthenia, nausea, vomiting, weight loss, depression, appetite loss, diabetes mellitus, 
jaundice, carbohydrate antigen 19-9 (CA 19-9), carcinoembryonic antigen (CEA), gamma-glutamyl 
transferase (GGT), glucose, alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
alkaline phosphatase (ALP), albumin and bilirubin. Learning from rule based method designed by 
Chen et al. to calculate associations among biological terms [H, et al, 2004], Keyword-based 
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method was used to automatically extract and classify PubMed abstracts that mentioned both any of 
the risk factors and pancreatic cancer together to calculate the weight of each risk factor. Each 
PubMed abstract was classified into one of the following three categories according to the 
association between the selected variable and pancreatic cancer: positive, negative, or neutral 
association. To ensure high accuracy in the abstract classification phase, the machine classification 
results were further reviewed manually and corrected as appropriate, although the manual review 
was greatly enhanced by the text-mining algorithm since the sentences containing the keywords 
were automatically highlighted to ease the manual review. For each risk factor, only the abstracts 
containing positive and negative associations between the risk factor and pancreatic cancer were 
used to calculate the original weights for each risk factor. Each risk factor is treated as a binary 
variable without considering the severity, degree, accumulative length, or other quantitative 
information of the risk factor. The value “true” represents the presence of a factor and the value 
“false” represents the absence of a risk factor. 
 
Results and Discussion 
The top three variables associated with pancreatic cancer, ranked by importance, were: weight loss, 
abnormal glucose, and abnormal CA 19-9. In contrast to the PubMed weighting results, the top three 
most frequent variables appearing in pancreatic cancer patients EHR were: glucose, albumin, and 
nausea. Accuracy indicated by weighted BNI (91%) is significantly higher than conventional BNI 
(80.6%), KNN (71.8%) and SVM (72.7%). As shown in Figure 2, ROC curve of the weighted BNI is 
higher than that of the conventional BNI, KNN and SVM, indicating a better performance is achieved 
by the weighted BNI for pancreatic cancer prediction. 
 
 
 
 
 
 
Figure 1: Comparison of ROC curves of the weighted BNI, the conventional BNI, KNN and SVM 
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3. RESEARCH HYPOTHESIS AND OBJECTIVES 
           Research Objective: 
 Given the technical gaps discussed previously, the work reported here begins to bridge this gap by 
utilizing extra components: family history, acquired hereditary disorders, endless pancreatitis, cirrhosis 
of the liver, stomach issues, abstain from food, physical dormancy, caffeine intake alongside existing 
elements. For example, age, liquor or cigarette use, stomach agony, weariness or asthenia, weight 
reduction, diabetes mellitus, jaundice, sugar antigen 19-9 (CA 19-9), carcinoembryonic antigen (CEA), 
gamma-glutamyl transferase (GGT), glucose, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), basic phosphatase (ALP), HGVSp_Short, cDNA_position, CDS_position, 
ENSP, UNIPARC, EXON to make clinical and genomic dataset comprising of subset of these elements. 
Then use Support Vector Machine classifier on these datasets first individually and later by combining 
both the datasets to make predictions about pancreatic cancer. Based on the technical Gap, Null and 
Alternate Hypothesis are stated below  
 
Alternate Hypothesis:  
Support Vector Machine as a classification algorithm will improve prediction accuracy of pancreatic 
cancer model by approximately 5% if combination of subset of features mentioned above in the research 
objective is used. 
 
Null Hypothesis:  
Support Vector Machine as a classification algorithm will not improve prediction accuracy of pancreatic 
cancer by 5% if combination of subset of features mentioned above in the research objective is used. 
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4. EXPERIMENTAL DESIGN 
     The experiments defined below are intended to test the hypothesis posited above. All experiments will   
      measure the effect of carrying out the experiments by employing the metrics described below. 
1. Calculate accuracy of Pancreatic Cancer Prediction Model on Clinical Dataset 
2. Calculate accuracy of Pancreatic Cancer Prediction Model on Genomic Dataset   
3. Create Synthetic dataset of Clinical features 
4. Derive features using various combinations of features in Synthetic Clinical dataset 
5. Derive features using various combinations of features in Genomic dataset 
6. Make Predictions on the combination of Synthetic Clinical and Genomic datasets 
 
 
5. APPROACH AND METHOD 
    For conducting the experiments, four real datasets and one synthetic dataset are used.  
    5.1. QCMG Data Set 
This data is obtained from “cbioportal”. Data set consists of both clinical as well as genomic    
data. It has 383 clinical samples. Mutation data file consists of 22763 samples and 115 features per   
sample. There are two separate files for clinical and genomic data each. Clinical data consists of  
features like patient_id, ethnicity, sex, age, smoker, country, etc. Genomic data file consists of  
features like Gene_Id, Chromosome, Variant_type, start_position, end_position, reference_allele,  
etc.  
 
In the dataset, 60 features from 115 features consisted of more than 50% missing values so these   
features are removed. Also removed missing values for remaining features in the dataset. After   
processing, the dataset size is 8994 x 53.  
 
Visualized combination of various features using heat map in order to identify important features   
related to the dependent variable i.e. pancreatic cancer. Following heat map shows the correlation   
between various features. As it can be seen from the heat maps that none of the features are   
strongly correlated to the dependent variable i.e. STATUS  
 
Page 23 of 42 
 
 
 
Figure 2: Heat Map of features 
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Figure 3: Heat Map of features 
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Figure 4: Heat Map of features 
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Figure 5: Heat Map of features 
 
    5.2. TCGA Data Set 
           This dataset is obtained from “cbioportal”. Dataset consists of separate files for mutation and   
             clinical data. Clinical data has 184 samples with 23 features for each sample. Clinical dataset has   
             features like Gender, Race, Ethnicity, Alcohol_History, Diabetes, Family_History_of_Cancer.   
             Genomic dataset consisted of similar features as mentioned above in QCMG data. 
 
            The dataset did not contain any missing values. Before visualizing the data, converted the     
            categorical features to numeric using LabelEncoder. Visualized clinical data using heat map as   
            shown below. It can be seen from the heat map that none of the features is strongly correlated with  
            the dependent variable which in this case is ‘VITAL_STATUS’. 
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 Figure 6: TCGA dataset features Heat Map 
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    5.3. PLCO Data Set  
            This dataset is obtained from NCI Cancer Data Access System. It is a clinical dataset        
             of 1,54,897 patients and 154 features per patient. Features consists of age, sex, panc_cancer,    
             marital, cigarette_status, family_cancer_history, diabetes, liver_comorbity, etc.  
 
             The important features that are identified from list of 154 features based on the hypothesis are  
             Age, Participant's current cigarette smoking status, The total number of years the participant  
             smoked, # of Cigarettes Smoked Per Day, Age Started Smoking, Has Family History of      
             Any Cancer, Family History of Pancreatic Cancer, Diabetes, Liver Comorbidities, Age   
             stopped smoking, Drink Alcohol, Caffeine, Glucose. Removed missing values for all the  
             above mentioned features. Visualized the data using heatmaps to find out correlation  
             between these features and dependent variable. Also plotted scatter plots to find relationship  
             between variables. After carefully looking at the data, it is observed that the dataset is highly  
             imbalanced. 98 % records belong to class 0 (Non Cancer) and 2 % belong to class 1  
             (Cancer).    
 
            Plotted the data on a scatter plot to identify relationship between variables. As  
            shown in the scatter plot below, the relationship between variables is not linear. 
            Heat map is used in order to identify important variables related to dependent variable i.e.   
            Pancreatic Cancer status. It can be inferred from the heat map below that none of the  
            variables is highly correlated to the dependent variable.  
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Figure 7: PLCO dataset features Heat Map 
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Figure 8: TCGA dataset Correlation Matrix 
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5. APPROACH AND METHOD 
    5.4. Clinical Synthetic Data: 
           Since none of the datasets mentioned above helped in predicting Pancreatic Cancer, Synthetic      
            dataset of clinical features is created as mentioned below: 
o Unexpected Weight Loss: 1 – No, 2 – Moderate, 3 – Significant 
o Smoking: 0 – Non smoker, 1 – Light, 2 – Heavy 
o Jaundice: 0 – No, 1 – Yes 
o Floating Bowels: 0 – No, 1 – Yes 
o Itchy Skin: 0 – No, 1 – Moderate, 2 – High 
o Blood clot in leg: 0 – No, 1 – Small, 2 – Big 
o Liver Enlargement: 0 – No, 1 – Yes 
 
            These are strong clinical symptoms of Pancreatic Cancer. Since pancreatic cancer is  
             hard to detect, any one symptom is not a very strong indicator of cancer. Hence various  
             combinations of these features along with their individual  
             contribution are considered. 90 % of data belongs to class 0 (Non pancreatic Cancer) and 10 %    
             data belongs to class 1 (Pancreatic Cancer). 
 
             Data is visualized using heatmap in order to obtain importance of individual  
             features and their combination. As it can be seen from the heatmap that the combination   
             of features is strongly correlated to the dependent variable i.e. cancer than any  
             individual feature. 
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Figure 9: Synthetic dataset features Heat Map 
                        
            
            Various features are derived as a combination of above mentioned features. For  
            example ‘Combination_Wieght_Smoking’ is a combined feature of ‘Weight’ and   
            ‘Smoking’. Other derived features are ‘Combination_Weight_Jaundice’,  
            ‘Combination_Smoking_Jaundice’, ‘Smoking_Weight_Jaundice_Bowels’, etc. The values   
            for any combined feature is calculated by taking mean of the individual features. And the   
            pancreatic cancer value is assigned to a particular record based on whether majority of its                         
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            predictor variables values are in favor of pancreatic cancer or not. In all the shape of the   
            dataset is 400 x 16 i.e. 400 samples with 16 variables for each sample. 
 
           Support Vector Machine Binary Classifier is used to make predictions. Before  
            building the model, the dataset was split into Training data (70 %) and Testing data (30 %).   
            The predictor variables and dependent variable are separated in training and testing data. 
            Support Vector Machine ‘Linear’ kernel is used for building the model. The model is    
            trained on 70 % training data and validated on remaining 30 % data. The model has been   
            evaluated on metrics like accuracy, precision, recall and area under curve (auc) score.    
 
  
6. RESULTS 
    Experiments with multiple datasets are conducted as mentioned in the above section and below are the    
     results with each one of them. 
    6.1 PLCO Dataset Results 
           Since this dataset is highly imbalanced i.e. only 0.47 % belongs to class 1 (Pancreatic Cancer), 
           following approaches are considered: 
          Subset of features: 
           Since the dataset consisted of 154 features, various subsets of features are considered. Since  
           abnormal weight loss is a prominent symptom of cancer, feature ‘weight difference’ is derived using     
           ‘weight_at_20’ and ‘weight_at_50’ features. Support Vector Machine Classifier is used to make   
           predictions and result is as follows 
 
Metric   Value Explanation 
Precision Class 0 0.99 Given a class 0 prediction from the classifier, how likely is it to be correct 
  Class 1 0 Given a class 1 prediction from the classifier, how likely is it to be correct 
Recall Class 0 1 Given a class 0 sample, how likely will the classifier detect it 
  Class 1 0 Given a class 1 sample, how likely will the classifier detect it 
Accuracy   99.52% Ratio of correct predictions to total predictions 
AUC 
Score   0.5 Area Under Reciever Operating Characteristic Curve 
            
Table 4: PLCO Data Results for Subset of Features 
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           Since this feature is not correlated with Pancreatic Cancer, the results are not good. The  
           accuracy is so high because the data set is highly imbalanced and it classifies almost every  
           sample as class 0. 
                      
           Smoking is another prominent symptom for pancreatic cancer. The dataset contained features     
           like ‘no. of years smoked’ and ‘no. of cigarettes smoked per day’. Using these a new feature 
           ‘total cigarette smoked’ is derived and have made predictions using it. There is no correlation at all  
           between this feature and the dependent variable. Couple of other features like  
           ‘family_history_cancer’, ‘liver_comorbidity’ along with ‘total cigarette smoked’ are also considered  
           and following are the results of SVM classifier: 
 
Metric   Value Explanation 
Precision Class 0 0.99 Given a class 0 prediction from the classifier, how likely is it to be correct 
  Class 1 0 Given a class 1 prediction from the classifier, how likely is it to be correct 
Recall Class 0 1 Given a class 0 sample, how likely will the classifier detect it 
  Class 1 0 Given a class 1 sample, how likely will the classifier detect it 
Accuracy   99.54% Ratio of correct predictions to total predictions 
AUC 
Score   0.5 Area Under Reciever Operating Characteristic Curve 
                   
Table 5: PLCO Data Results for Subset of Features 
 
           Dataset is balanced by undersampling the majority class features. The new dataset  
           consists of 692 class 0 and 692 class 1 samples. Support Vector Machine classifier results   
           are as follows: 
 
Metric   Value Explanation 
Precision Class 0 0.55 Given a class 0 prediction from the classifier, how likely is it to be correct 
  Class 1 0.58 Given a class 1 prediction from the classifier, how likely is it to be correct 
Recall Class 0 0.51 Given a class 0 sample, how likely will the classifier detect it 
  Class 1 0.62 Given a class 1 sample, how likely will the classifier detect it 
Accuracy   56.73% Ratio of correct predictions to total predictions 
AUC 
Score   0.56 Area Under Reciever Operating Characteristic Curve 
            
Table 6: PLCO Data Results with Undersampling 
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           In this case, the accuracy is less since the dataset consists of equal number of class 0 and class  
           1 samples. However the Precision and Recall values have improved as the probability of the   
           classifier predicting the correct class for each sample is high. 
 
           Top correlating features with the dependent variable are: 'HGVSp_Short' ,'cDNA_position',  
           CDS_position', 'ENSP', 'UNIPARC', 'EXON'. This subset of features is used to build a    
           SVM model and make predictions. Results are as follows: 
                      
Metric   Value Explanation 
Precision Class 0 0.81 Given a class 0 prediction from the classifier, how likely is it to be correct 
  Class 1 0.2 Given a class 1 prediction from the classifier, how likely is it to be correct 
Recall Class 0 0.99 Given a class 0 sample, how likely will the classifier detect it 
  Class 1 0 Given a class 1 sample, how likely will the classifier detect it 
Accuracy   80.77% Ratio of correct predictions to total predictions 
AUC 
Score   0.5 Area Under Reciever Operating Characteristic Curve 
 
Table 7: Results with Genomic Data 
 
           Weighted Classification: 
            Since the dataset is highly imbalanced, have assigned weights to the minority class samples  
            i.e. class 1. This is achieved in Support Vector Machines by using the parameter  
            ‘class_weight = balanced’. This replicates the smaller class until there are as many samples as  
            in the larger one but in an implicit way. Results for this are as follows: 
 
Metric   Value Explanation 
Precision Class 0 0.99 Given a class 0 prediction from the classifier, how likely is it to be correct 
  Class 1 0.01 Given a class 1 prediction from the classifier, how likely is it to be correct 
Recall Class 0 0.58 Given a class 0 sample, how likely will the classifier detect it 
  Class 1 0.54 Given a class 1 sample, how likely will the classifier detect it 
Accuracy   58.04% Ratio of correct predictions to total predictions 
AUC 
Score   0.56 Area Under Reciever Operating Characteristic Curve 
                     
Table 8: Results with Weighted Classification 
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    6.2 Synthetic Clinical Data Results 
           This dataset consists of 400 samples and 16 features. It has 10 % data for class 1 i.e. having cancer  
           and 90 % data for class 0 i.e. not having cancer. Have applied support vector machine classification   
           and following are the results along with ROC plot for synthetic clinical data results: 
 
Metric   Value Explanation 
Precision Class 0 0.93 Given a class 0 prediction from the classifier, how likely is it to be correct 
  Class 1 1 Given a class 1 prediction from the classifier, how likely is it to be correct 
Recall Class 0 1 Given a class 0 sample, how likely will the classifier detect it 
  Class 1 0.33 Given a class 1 sample, how likely will the classifier detect it 
Accuracy   93.33% Ratio of correct predictions to total predictions 
AUC 
Score   0.67 Area Under Reciever Operating Characteristic Curve 
          
Table 9: Results with Synthetic Clinical Data 
 
 
 
Figure 10: Receiver Operating Characteristic Curve for Synthetic Clinical Data 
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   6.3 Real Genomic and Clinical Synthetic Data Results 
    Genomic data from QCMG and Synthetic Clinical data are combined. Features used from Genomic data  
          are: 'HGVSp_Short', 'cDNA_position', 'CDS_position', 'ENSP', 'UNIPARC', 'EXON'. A prediction model  
          is built using Support Vector Machines Classifier and following are the results:  
            
Metric   Value Explanation 
Precision Class 0 0.91 Given a class 0 prediction from the classifier, how likely is it to be correct 
  Class 1 0 Given a class 1 prediction from the classifier, how likely is it to be correct 
Recall Class 0 1 Given a class 0 sample, how likely will the classifier detect it 
  Class 1 0 Given a class 1 sample, how likely will the classifier detect it 
Accuracy   90.83% Ratio of correct predictions to total predictions 
AUC 
Score   0.5 Area Under Reciever Operating Characteristic Curve 
          
Table 10: Clinical Data and only Individual Genomic features 
 
Metric   Value Explanation 
Precision Class 0 0.89 Given a class 0 prediction from the classifier, how likely is it to be correct 
  Class 1 0 Given a class 1 prediction from the classifier, how likely is it to be correct 
Recall Class 0 1 Given a class 0 sample, how likely will the classifier detect it 
  Class 1 0 Given a class 1 sample, how likely will the classifier detect it 
Accuracy   89.16% Ratio of correct predictions to total predictions 
AUC 
Score   0.5 Area Under Reciever Operating Characteristic Curve 
 
Table 11: Clinical Data and (Individual + Derived) Genomic features 
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7. DISCUSSION 
From the results, it can be seen that it is important to have relevant features in order to predict Pancreatic 
Cancer. Also, no individual feature is a strong symptom of pancreatic cancer and we need a combination 
of features to make predictions. In the Synthetic data experiments, individual features like Jaundice, 
Weight Loss, etc. are not strongly correlated with the dependent variable. Hence one cannot make 
predictions based only on these variables. However a combination of these features like combination of 
Jaundice and Smoking, Combination of Smoking and Weight Loss, etc. is more strongly correlated to 
pancreatic cancer than individual features. As we combine more number of features, it is observed that 
the correlation increases. Thus we can say that a combination of more number of clinical features is a 
good predictor of Pancreatic Cancer than individual features. 
The mutation data used in this work is not a good predictor of Pancreatic Cancer since none of the 
features is correlated to the dependent variable. Even when the weakly correlated genomic data is 
combined with strongly correlated synthetic clinical data, the results are not good. Thus it is necessary to 
have a good dataset of genomic features so that a combination of genomic and clinical data might have 
better prediction accuracy. 
 
8. CONCLUSION AND FUTURE WORK 
For Synthetic Clinical data, prediction results are good when a combination of features is used. For 
genomic data, the prediction results are not good since it is very weakly correlated to the dependent 
variable. Moreover the results degrade when synthetic clinical and real genomic features are combined 
together. Thus in the real world if a good combination of clinical and genomic features is considered 
then Pancreatic Cancer can be predicted accurately. However, based on the results obtained in this study, 
the Hypothesis that “Combination of Clinical and Genomic features will improve the prediction 
accuracy of Pancreatic Cancer by 5 %” is refuted.  
In the future, plan to collect and conduct experiments on more significant real world genomic data. Also 
plan to incorporate additional clinical features to build a better model. Future work will also include 
calculating p-value to determine statistical significance in a hypothesis test. p-value will evaluate how 
well the sample data support that the null hypothesis is true. A high p-value suggests that the sample 
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data provides enough evidence to accept null hypothesis for the entire population while a low p-value 
suggests evidence to reject null hypothesis.  
 
 
9. PROJECT SCHEDULE 
Complete project implementation took around 3-4 months. Inside this time allotment every one of the 
tasks specified in the strategy and approach area of the report were completed. A fundamental Pancreatic 
Cancer Prediction model was produced using Support Vector Machines before fifth week. Before 10 
weeks' over every one of the tasks mentioned in the design of experiments were finished. Remaining 
time was spent for composing the report. A more point by point timetable is described in the table 
below. 
 
EXPERIMENTS  WEEK 
DATA SET EXPLORATION 0-1 
LOADING DATA SET AND MORE EXPLORATION 1-2 
DATA PREPROCESSING AND FEATURE 
ENGINEERING 
3-4 
APPLYING SVM ON THIS MODEL 4-5 
FINE TUNING SVM PARAMETERS 5-6 
OTHER DATA SETS EXPLORATION 6-7 
MORE DATA PROCESSING AND EXPERIMENTS 
WITH MULTIPLE DATASETS 
7-9 
CREATING SYNTHETIC DATA AND BUILDING 9-10 
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MODEL  
PROJECT REPORT 10-12 
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